Short Interest in Genmab A/S (NASDAQ:GMAB) Rises By 32.5%

Genmab A/S (NASDAQ:GMAB) was the target of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 3,060,000 shares, a growth of 32.5% from the February 28th total of 2,310,000 shares. Based on an average daily trading volume, of 1,460,000 shares, the short-interest ratio is currently 2.1 days. Currently, 0.5% of the shares of the company are sold short.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Deep Track Capital LP acquired a new position in shares of Genmab A/S during the 4th quarter valued at about $41,740,000. Brandywine Global Investment Management LLC purchased a new position in Genmab A/S during the fourth quarter worth about $33,804,000. Two Sigma Advisers LP boosted its holdings in Genmab A/S by 168.8% in the 4th quarter. Two Sigma Advisers LP now owns 1,653,500 shares of the company’s stock valued at $34,509,000 after purchasing an additional 1,038,400 shares during the last quarter. Two Sigma Investments LP boosted its holdings in Genmab A/S by 122.2% in the 4th quarter. Two Sigma Investments LP now owns 1,706,364 shares of the company’s stock valued at $35,612,000 after purchasing an additional 938,455 shares during the last quarter. Finally, Marshall Wace LLP grew its stake in shares of Genmab A/S by 162.2% in the 4th quarter. Marshall Wace LLP now owns 1,122,296 shares of the company’s stock valued at $23,422,000 after buying an additional 694,243 shares during the period. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Stock Performance

Shares of GMAB traded down $0.57 during trading hours on Tuesday, hitting $19.02. 754,303 shares of the stock were exchanged, compared to its average volume of 957,581. The stock’s 50-day moving average price is $20.87 and its two-hundred day moving average price is $21.79. Genmab A/S has a 12-month low of $18.64 and a 12-month high of $30.50. The company has a market cap of $12.58 billion, a price-to-earnings ratio of 10.93, a price-to-earnings-growth ratio of 2.65 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. On average, research analysts expect that Genmab A/S will post 1.45 earnings per share for the current year.

Analyst Ratings Changes

GMAB has been the topic of several analyst reports. Truist Financial dropped their target price on Genmab A/S from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Tuesday, March 11th. William Blair raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 11th. Leerink Partners upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 target price for the company in a research note on Thursday, February 13th. BNP Paribas raised Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 11th. Finally, Sanford C. Bernstein lowered Genmab A/S from a “market perform” rating to an “underperform” rating in a report on Tuesday. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $41.33.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.